Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells

Idelalisib is a targeted agent that potently inhibits PI3Kδ which is exclusively expressed in hematological cells. Bendamustine is a well-tolerated cytotoxic alkylating agent which has been extensively used for treatment of chronic lymphocytic leukemia (CLL). Both these agents are FDA-approved for C...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Oncotarget
Main Authors: Modi, Prexy, Balakrishnan, Kumudha, Yang, Qingshan, Wierda, William G., Keating, Michael J., Gandhi, Varsha
Format: Artigo
Sprog:Inglês
Udgivet: Impact Journals LLC 2017
Fag:
Research Paper
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5369961/
https://ncbi.nlm.nih.gov/pubmed/28187444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15180
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker